Top

BMC Geriatrics

Published in:

Open Access 01-12-2024 | Dementia | Research

Potentially inappropriate prescribing for people with dementia in ambulatory care: a cross-sectional observational study

Authors: Nahla A. Alageel, Carmel M. Hughes, Monira Alwhaibi, Walid Alkeridy, Heather E. Barry

Published in: BMC Geriatrics | Issue 1/2024

Abstract

Background

Studies have shown that potentially inappropriate prescribing (PIP) is highly prevalent among people with dementia (PwD) and linked to negative outcomes, such as hospitalisation and mortality. However, there are limited data on prescribing appropriateness for PwD in Saudi Arabia. Therefore, we aimed to estimate the prevalence of PIP and investigate associations between PIP and other patient characteristics among PwD in an ambulatory care setting.

Methods

A cross-sectional, retrospective analysis was conducted at a tertiary hospital in Saudi Arabia. Patients who were ≥ 65 years old, had dementia, and visited ambulatory care clinics between 01/01/2019 and 31/12/2021 were included. Prescribing appropriateness was evaluated by applying the Screening Tool of Older Persons Potentially Inappropriate Prescriptions (STOPP) criteria. Descriptive analyses were used to describe the study population. Prevalence of PIP and the prevalence per each STOPP criterion were calculated as a percentage of all eligible patients. Logistic regression analysis was used to investigate associations between PIP, polypharmacy, age and sex; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Analyses were conducted using SPSS v27.

Results

A total of 287 PwD were identified; 56.0% (n = 161) were female. The mean number of medications prescribed was 9.0 [standard deviation (SD) ± 4.2]. The prevalence of PIP was 61.0% (n = 175). Common instances of PIP were drugs prescribed beyond the recommended duration (n = 90, 31.4%), drugs prescribed without an evidence-based clinical indication (n = 78, 27.2%), proton pump inhibitors (PPIs) for > 8 weeks (n = 75, 26.0%), and acetylcholinesterase inhibitors with concurrent drugs that reduce heart rate (n = 60, 21.0%). Polypharmacy was observed in 82.6% (n = 237) of patients and was strongly associated with PIP (adjusted OR 24.1, 95% CI 9.0–64.5).

Conclusions

Findings have revealed a high prevalence of PIP among PwD in Saudi Arabia that is strongly associated with polypharmacy. Future research should aim to explore key stakeholders’ experiences and perspectives of medicines management to optimise medication use for this vulnerable patient population.

Available only for authorised users

World Health Organization. Dementia fact sheets, World Health Organization. 2022. Accessed 11 Jan 2023. https://www.who.int/news-room/fact-sheets/detail/dementia

Nichols E, Steinmetz JD, Vollset SE, Fukutaki K, Chalek J, Abd-Allah F, et al. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the global burden of disease study 2019. Lancet Public Health. 2022;7(2):e105–25. https://doi.org/10.1016/S2468-2667(21)00249-8CrossRef

World Health Organization. Health data overview for the Kingdom of Saudi Arabia. 2019. Accessed 30 Nov 2023. https://data.who.int/countries/682

Topinková E. Aging, disability and frailty. Ann Nutr Metab. 2008;52:6–11. https://doi.org/10.1159/000115340CrossRefPubMed

Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9. https://doi.org/10.1016/j.arr.2011.03.003CrossRefPubMed

Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95. https://doi.org/10.1016/j.jclinepi.2012.02.018CrossRefPubMed

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https://doi.org/10.1186/s12877-017-0621-2CrossRefPubMedPubMedCentral

Bunn F, Burn A-M, Goodman C, Rait G, Norton S, Robinson L, et al. Comorbidity and dementia: a scoping review of the literature. BMC Med. 2014;12(1):192. https://doi.org/10.1186/s12916-014-0192-4CrossRefPubMedPubMedCentral

Browne J, Edwards DA, Rhodes KM, Brimicombe DJ, Payne RA. Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study. BMJ Open. 2017;7(3):e012546. https://doi.org/10.1136/bmjopen-2016-012546CrossRefPubMedPubMedCentral

10.

Clague F, Mercer SW, McLean G, Reynish E, Guthrie B. Comorbidity and polypharmacy in people with dementia: insights from a large, population-based cross-sectional analysis of primary care data. Age Ageing. 2017;46(1):33–9. https://doi.org/10.1093/ageing/afw176CrossRefPubMed

11.

Leelakanok N, D’Cunha RR. Association between polypharmacy and dementia - a systematic review and metaanalysis. Aging Ment Health. 2019;23(8):932–41. https://doi.org/10.1080/13607863.2018.1468411CrossRefPubMed

12.

Growdon ME, Gan S, Yaffe K, Steinman MA. Polypharmacy among older adults with dementia compared with those without dementia in the United States. J Am Geriatr Soc. 2021;69(9):2464–75. https://doi.org/10.1111/jgs.17291CrossRefPubMedPubMedCentral

13.

Wastesson JW, Morin L, Tan ECK, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opin Drug Saf. 2018;17(12):1185–96. https://doi.org/10.1080/14740338.2018.1546841CrossRefPubMed

14.

Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining inappropriate medication use in nursing home residents. Ucla division of geriatric medicine. Arch Intern Med. 1991;151(9):1825–32.CrossRefPubMed

15.

Jano E, Aparasu RR. Healthcare outcomes associated with beers’ criteria: a systematic review. Ann Pharmacother. 2007;41(3):438–47. https://doi.org/10.1345/aph.1H473CrossRefPubMed

16.

Hill-Taylor B, Walsh KA, Stewart S, Hayden J, Byrne S, Sketris IS. Effectiveness of the Stopp/Start (screening tool of older persons’ potentially inappropriate prescriptions/screening tool to alert doctors to the right treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016;41(2):158–69. https://doi.org/10.1111/jcpt.12372CrossRefPubMed

17.

Hyttinen V, Jyrkkä J, Valtonen H. A systematic review of the impact of potentially inappropriate medication on health care utilization and costs among older adults. Med Care. 2016;54(10):950–64. https://doi.org/10.1097/mlr.0000000000000587CrossRefPubMed

18.

Liew TM, Lee CS, Goh Shawn KL, Chang ZY. Potentially inappropriate prescribing among older persons: a meta-analysis of observational studies. Ann Fam Med. 2019;17(3):257–66. https://doi.org/10.1370/afm.2373CrossRefPubMedPubMedCentral

19.

Xing XX, Zhu C, Liang HY, Wang K, Chu YQ, Zhao LB, et al. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: a systematic review and meta-analysis. Ann Pharmacother. 2019;53(10):1005–19. https://doi.org/10.1177/1060028019853069CrossRefPubMed

20.

O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. Stopp/Start criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145CrossRefPubMed

21.

Arlt S, Lindner R, Rösler A, von Renteln-Kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25(12):1033–47. https://doi.org/10.2165/0002512-200825120-00005CrossRefPubMed

22.

El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication adherence in older patients with dementia: a systematic literature review. J Pharm Pract. 2018;31(3):322–34. https://doi.org/10.1177/0897190017710524CrossRefPubMed

23.

Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;3:73. https://doi.org/10.3389/fneur.2012.00073CrossRefPubMedPubMedCentral

24.

Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, et al. Neuropsychiatric symptoms in alzheimer’s disease. Alzheimers Dement. 2011;7(5):532–9. https://doi.org/10.1016/j.jalz.2011.05.2410CrossRefPubMed

25.

Maust DT, Strominger J, Kim HM, Langa KM, Bynum JPW, Chang CH, et al. Prevalence of central nervous system-active polypharmacy among older adults with dementia in the US. JAMA. 2021;325(10):952–61. https://doi.org/10.1001/jama.2021.1195CrossRefPubMed

26.

Gnjidic D, Hilmer SN, Hartikainen S, Tolppanen AM, Taipale H, Koponen M, et al. Impact of high risk drug use on hospitalization and mortality in older people with and without alzheimer’s disease: a national population cohort study. PLoS ONE. 2014;9(1):e83224. https://doi.org/10.1371/journal.pone.0083224CrossRefPubMedPubMedCentral

27.

McMichael AJ, Zafeiridi E, Ryan M, Cunningham EL, Passmore AP, McGuinness B. Anticholinergic drug use and risk of mortality for people with dementia in Northern Ireland. Aging Ment Health. 2021;25(8):1475–82. https://doi.org/10.1080/13607863.2020.1830028CrossRefPubMed

28.

Barry HE, Cooper JA, Ryan C, Passmore AP, Robinson AL, Molloy GJ, et al. Potentially inappropriate prescribing among people with dementia in primary care: a retrospective cross-sectional study using the enhanced prescribing database. J Alzheimers Dis. 2016;52(4):1503–13. https://doi.org/10.3233/JAD-151177CrossRefPubMed

29.

Delgado J, Bowman K, Clare L. Potentially inappropriate prescribing in dementia: a state-of-the-art review since 2007. BMJ Open. 2020;10(1). https://doi.org/10.1136/bmjopen-2019-029172

30.

Murphy C, Dyer AH, Lawlor B, Kennelly SP. Potentially inappropriate medication use in older adults with mild-moderate alzheimer’s disease: prevalence and associations with adverse events. Age Ageing. 2020;49(4):580–7. https://doi.org/10.1093/ageing/afaa067CrossRefPubMed

31.

Delgado J, Jones L, Bradley MC, Allan LM, Ballard C, Clare L, et al. Potentially inappropriate prescribing in dementia, multi-morbidity and incidence of adverse health outcomes. Age Ageing. 2021;50(2):457–64. https://doi.org/10.1093/ageing/afaa147CrossRefPubMed

32.

Liu AK, Possin KL, Cook KM, Lynch S, Dulaney S, Merrilees JJ, et al. Effect of collaborative dementia care on potentially inappropriate medication use: outcomes from the care ecosystem randomized clinical trial. Alzheimers Dement. 2022;10:1002. https://doi.org/10.1002/alz.12808CrossRef

33.

Al Odhayani A, Tourkmani A, Alshehri M, Alqahtani H, Mishriky A. Potentially inappropriate medications prescribed for elderly patients through family physicians. Saudi J Biol Sci. 2017;24(1):200–7. https://doi.org/10.1016/j.sjbs.2016.05.006CrossRefPubMed

34.

Jastaniah NA, Almaqati AS, Alsuraihi AK, Abughanim SA, Aseeri M. Inappropriate prescribing in elderly inpatients at a university hospital in Saudi Arabia. Drugs Real World Outcomes. 2018;5(4):211–6. https://doi.org/10.1007/s40801-018-0142-0CrossRefPubMedPubMedCentral

35.

Alhawassi TM, Alatawi W, Alwhaibi M. Prevalence of potentially inappropriate medications use among older adults and risk factors using the 2015 American Geriatrics Society Beers criteria. BMC Geriatr. 2019;19(1):154. https://doi.org/10.1186/s12877-019-1168-1CrossRefPubMedPubMedCentral

36.

Alturki A, Alaama T, Alomran Y, Al-Jedai A, Almudaiheem H, Watfa G. Potentially inappropriate medications in older patients based on Beers criteria: a cross-sectional study of a family medicine practice in Saudi Arabia. BJGP Open. 2020;4(1). https://doi.org/10.3399/bjgpopen20X101009

37.

WHO Collaborating Centre for Drug Statistics Methodolgy. Guidelines for ATC classification and DDD assignment. 2022. Oslo, Norway; 2021.

38.

IBM Corp. (2020) IBM SPSS Statistics for Windows VA, NY: IBM Corp. IBM SPSS statistics for windows. Armonk, NY: IBM Corp; 2020.

39.

Renom-Guiteras A, Thürmann PA, Miralles R, Klaaßen-Mielke R, Thiem U, Stephan A, et al. Potentially inappropriate medication among people with dementia in eight European countries. Age Ageing. 2018;47(1):68–74. https://doi.org/10.1093/ageing/afx147CrossRefPubMed

40.

Bala SS, Jamieson HA, Nishtala PS. Determinants of prescribing potentially inappropriate medications in a nationwide cohort of community dwellers with dementia receiving a comprehensive geriatric assessment. Int J Geriatr Psychiatry. 2019;34(1):153–61. https://doi.org/10.1002/gps.5004CrossRefPubMed

41.

Balkhi B, AlQahtani N, Alwhaibi M, Alshammari TM, Alhawassi TM, Mahmoud MA, et al. Prevalence and factors associated with polypharmacy use among adult patients in Saudi Arabia. J Patient Saf. 2021;17(8):e1119–24. https://doi.org/10.1097/pts.0000000000000439CrossRefPubMed

42.

Parsons C, Johnston S, Mathie E, Baron N, Machen I, Amador S, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29(2):143–55. https://doi.org/10.2165/11598560-000000000-00000CrossRefPubMed

43.

Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71(12):1415–27. https://doi.org/10.1007/s00228-015-1954-4CrossRefPubMed

44.

Patel T, Slonim K, Lee L. Use of potentially inappropriate medications among ambulatory home-dwelling elderly patients with dementia: a review of the literature. Can Pharm J (Ott). 2017;150(3):169–83. https://doi.org/10.1177/1715163517701770CrossRefPubMed

45.

Ho SW, Teng YH, Yang SF, Yeh HW, Wang YH, Chou MC, et al. Association of proton pump inhibitors usage with risk of pneumonia in dementia patients. J Am Geriatr Soc. 2017;65(7):1441–7. https://doi.org/10.1111/jgs.14813CrossRefPubMed

46.

Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182–96. https://doi.org/10.5056/jnm18001CrossRefPubMedPubMedCentral

47.

Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf. 2019;10:2042098618809927. https://doi.org/10.1177/2042098618809927CrossRefPubMed

48.

Sura SD, Carnahan RM, Chen H, Aparasu RR. Prevalence and determinants of anticholinergic medication use in elderly dementia patients. Drugs Aging. 2013;30(10):837–44. https://doi.org/10.1007/s40266-013-0104-xCrossRefPubMed

49.

Welsh TJ, van der Wardt V, Ojo G, Gordon AL, Gladman JRF. Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging. 2018;35(6):523–38. https://doi.org/10.1007/s40266-018-0549-zCrossRefPubMed

50.

Ablett AD, Wood AD, Barr R, Guillot J, Black AJ, Macdonald HM, et al. A high anticholinergic burden is associated with a history of falls in the previous year in middle-aged women: findings from the Aberdeen prospective osteoporosis screening study. Ann Epidemiol. 2018;28(8):557–e622. https://doi.org/10.1016/j.annepidem.2018.05.011CrossRefPubMed

51.

Tan ECK, Eriksdotter M, Garcia-Ptacek S, Fastbom J, Johnell K. Anticholinergic burden and risk of stroke and death in people with different types of dementia. J Alzheimers Dis. 2018;65(2):589–96. https://doi.org/10.3233/jad-180353CrossRefPubMed

52.

Meraya AM, Banji OJF, Khobrani MA, Alhossan A. Evaluation of psychotropic medications use among elderly with psychitric disorders in Saudi Arabia. Saudi Pharm J. 2021;29(6):603–8. https://doi.org/10.1016/j.jsps.2021.04.021CrossRefPubMedPubMedCentral

53.

Clyne B, Fitzgerald C, Quinlan A, Hardy C, Galvin R, Fahey T, et al. Interventions to address potentially inappropriate prescribing in community-dwelling older adults: a systematic review of randomized controlled trials. J Am Geriatr Soc. 2016;64(6):1210–22. https://doi.org/10.1111/jgs.14133CrossRefPubMed

54.

Campins L, Serra-Prat M, Gózalo I, López D, Palomera E, Agustí C, et al. Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract. 2017;34(1):36–42. https://doi.org/10.1093/fampra/cmw073CrossRefPubMed

55.

Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the d-prescribe randomized clinical trial. JAMA. 2018;320(18):1889–98. https://doi.org/10.1001/jama.2018.16131CrossRefPubMedPubMedCentral

56.

Reeve E, Trenaman SC, Rockwood K, Hilmer SN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13(6):651–68. https://doi.org/10.1080/17425255.2017.1325873CrossRefPubMed

57.

Bloomfield HE, Greer N, Linsky AM, Bolduc J, Naidl T, Vardeny O, et al. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35(11):3323–32. https://doi.org/10.1007/s11606-020-06089-2CrossRefPubMedPubMedCentral

58.

Ie K, Aoshima S, Yabuki T, Albert SM. A narrative review of evidence to guide deprescribing among older adults. J Gen Fam Med. 2021;22(4):182–96. https://doi.org/10.1002/jgf2.464CrossRefPubMedPubMedCentral

59.

McGrattan M, Ryan C, Barry HE, Hughes CM. Interventions to improve medicines management for people with dementia: a systematic review. Drugs Aging. 2017;34(12):907–16. https://doi.org/10.1007/s40266-017-0505-3CrossRefPubMed

60.

Shafiee Hanjani L, Long D, Peel NM, Peeters G, Freeman CR, Hubbard RE. Interventions to optimise prescribing in older people with dementia: a systematic review. Drugs Aging. 2019;36(3):247–67. https://doi.org/10.1007/s40266-018-0620-9CrossRefPubMed

61.

Sawan MJ, Moga DC, Ma MJ, Ng JC, Johnell K, Gnjidic D. The value of deprescribing in older adults with dementia: a narrative review. Expert Rev Clin Pharmacol. 2021;14(11):1367–82. https://doi.org/10.1080/17512433.2021.1961576CrossRefPubMed

62.

Aljawadi MH, Khoja AT, Alaboud NM, AlEnazi ME, Al-Shammari SA, Khoja TA, et al. Prevalence of polypharmacy and factors associated with it among Saudi older adults - results from the Saudi national survey for elderly health (SNSEH). Saudi Pharm J. 2022;30(3):230–6. https://doi.org/10.1016/j.jsps.2022.01.003CrossRefPubMedPubMedCentral

63.

Earl TR, Katapodis ND, Schneiderman SR, Shoemaker-Hunt SJ. Using deprescribing practices and the screening tool of older persons’ potentially inappropriate prescriptions criteria to reduce harm and preventable adverse drug events in older adults. J Patient Saf. 2020;16(1):S23–35. https://doi.org/10.1097/pts.0000000000000747CrossRefPubMedPubMedCentral

Title: Potentially inappropriate prescribing for people with dementia in ambulatory care: a cross-sectional observational study
Authors: Nahla A. Alageel
Carmel M. Hughes
Monira Alwhaibi
Walid Alkeridy
Heather E. Barry
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Dementia
Dementia
Published in: BMC Geriatrics / Issue 1/2024
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-024-04949-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

Psychometric properties of the Chinese version of the Hypertension Belief Assessment Tool

The association between physical activity and quality of life among people aged 60–89 living in own homes and nursing homes

Characteristics, outcomes, facilitators and barriers for psychosocial interventions on inpatient mental health dementia wards: a systematic review

‘In the shower crying…but we came back in the following day and did it all again’. Distress and resilience in care home staff during the COVID-19 pandemic– A qualitative interview study

Predictors of major adverse cardiac and cerebrovascular events after percutaneous coronary intervention in older adults: a systematic review and meta-analysis

Factors associated with social participation among community-dwelling frail older adults in Japan: a cross-sectional study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials